La Jolla Institute for Allergy and Immunology

Team studies how existing BCG vaccination could serve as foundation for new, more effective TB vaccines

A long, long time ago, the BCG vaccine was approved for use against tuberculosis (TB), and it's still given to infants today. For generations, the vaccine has saved lives and prevented untold suffering. And yet TB still kills around 1.5 million people every year. The problem is that the BCG vaccine was the first—and the last—vaccine approved to prevent tuberculosis.

Read More →

La Jolla Institute for Allergy and Immunology team receives $18 million consortium grant

LA JOLLA, CA, December 17, 2015 - The La Jolla Institute for Allergy and Immunology (LJI) is pleased to announce that an international team led by LJI investigator Alessandro Sette, Ph.D., is one of four recipients of a Human Immune Profiling Consortium (HIPC) grant in 2015. With this prestigious grant, the LJI team will characterize the immune response to dengue virus (DENV) and Mycobacterium tuberculosis (TB), both of which represent major global health challenges.

Read More →

Page 1 of 1 · Total posts: 2